Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
about
A minimal fragment of MUC1 mediates growth of cancer cellsDeregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiationCirculating tumor markers in breast cancer: accepted utilities and novel prospects.Developments in serologic detection of human pancreatic adenocarcinoma.Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelinePhysiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.Functional targeting of the MUC1 oncogene in human cancersCurrent approaches and challenges in monitoring treatment responses in breast cancer.Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy SubjectsCirculating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancer.Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.Elevated CA125 levels in patients with metastatic breast carcinoma.Use of mucin like cancer associated antigen (MCA) in the management of breast cancer.Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients.Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancerCharacterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene.A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice.An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma.Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.Evaluation of MSA as a serum marker in breast cancer: a comparison with CEA.Serum CA 15-3 assay in the diagnosis and follow-up of breast cancerCirculating CA 15-3 antigen levels in non-mammary malignancies.An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer.Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer.CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.Serological diagnosis of liver metastasis in patients with breast cancer.Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.Simple method for comparing reliability of two serum tumour markers in breast carcinomaTesting breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Liquid biopsy: unlocking the potentials of cell-free DNA.A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.Objective measurement of therapeutic response in breast cancer using tumour markers.Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.Various sulfated carbohydrate tumor marker candidates identified by focused glycomic analyses.Analysis of cytosol CA15-3, carcinoembryonic antigen, estrogen and progesterone receptors in breast cancer tissues.
P2860
Q21562292-10148FE5-A0EE-4FE2-9CBD-345257D079DDQ24675101-EEEE222F-70C0-4F24-A087-19868CFF7E7CQ33538453-2A408CD9-5FE6-4EE7-A46C-F73740C4D624Q33752171-0FF3DCB4-2A3E-4F84-9FEA-45F5705CAFCBQ33817285-D9180C3C-597E-4F51-8FC2-6B58D047F6CEQ34370883-13BEAAAA-54BD-4CBB-A48E-E5E754F37241Q34558072-30819EA2-37C8-4632-9A89-890CC10BF6AFQ34658727-6A5F3A14-0F5E-4C7E-A2B1-AD3E30FD87AFQ35117713-42E19A5B-88DC-4147-99FC-92573CA2E119Q35519793-9C76877A-136E-45C8-A83E-AFEFBF13D34EQ35703590-3B51E65E-60BA-46D2-A6A5-C4EE2644C226Q35977830-0F847A62-BD26-43A2-B796-80D1DDEE6D52Q35982073-3A1B2505-92C2-44BC-B976-A93077A6A62BQ35984825-8628FC73-6626-4874-BEEE-294371401AC1Q35998450-03466315-326F-435D-8A1B-E028F97BFE51Q36029476-FC54CF23-2583-4555-8083-86354DD90169Q36042743-6267842A-879A-4BCF-BD3E-F587E7CCFB08Q36080814-4C3905F7-C985-4252-A74E-AC2045E96CB4Q36081093-5DC95C0A-E8C2-4721-8828-B309C06692EEQ36393209-DB9C73AC-36B1-4DC2-95BC-288DCAAED35AQ36466048-619276B1-684C-4428-9491-6382D6BAB0FCQ36466612-5B19CE6D-3FC4-4451-BF38-7C9CBD57E4FBQ36467062-323F4028-D9BE-4964-B453-09570AC4F97CQ36467766-40C7B958-CBCE-4053-8E77-BD274AF95DD1Q36573275-B0D87E0D-9506-4C7F-A7FA-9EC63A5FE1B6Q36813625-C6A67427-CEA8-443A-84E3-2A44722E636FQ36814331-3A6D53BB-E3B6-4973-B602-7FDADF288395Q37234788-6AB4B277-9E81-4C97-B923-03CC3CA1C118Q37246378-854DE1C5-21B3-4DA8-94AB-AFFCC5613537Q37655098-BB35E441-88D4-446E-9AEB-2309D868ED91Q38109808-13A6610C-B737-427E-8A07-DCDB1195A55AQ39279845-4477E4CB-E8C9-442D-83E0-A350CEC26655Q39532654-7F609017-96BB-4054-BF00-B01459AF3BC3Q42281537-1496A53B-9268-434D-A697-757FFA48447DQ50001301-A007A951-A90D-4B8F-B96D-99977C0F1282Q53609090-7E95D1B7-5BFA-4CF0-B332-2F9C3E0E4792Q55391588-135BC48B-5CE9-403C-BECE-11FD8C09A5D1
P2860
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
description
1986 nî lūn-bûn
@nan
1986 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Comparison of circulating CA15 ...... n patients with breast cancer.
@ast
Comparison of circulating CA15 ...... n patients with breast cancer.
@en
Comparison of circulating CA15 ...... n patients with breast cancer.
@nl
type
label
Comparison of circulating CA15 ...... n patients with breast cancer.
@ast
Comparison of circulating CA15 ...... n patients with breast cancer.
@en
Comparison of circulating CA15 ...... n patients with breast cancer.
@nl
prefLabel
Comparison of circulating CA15 ...... n patients with breast cancer.
@ast
Comparison of circulating CA15 ...... n patients with breast cancer.
@en
Comparison of circulating CA15 ...... n patients with breast cancer.
@nl
P2093
P1476
Comparison of circulating CA15 ...... n patients with breast cancer.
@en
P2093
P304
P356
10.1200/JCO.1986.4.10.1542
P407
P577
1986-10-01T00:00:00Z